Israel’s Pepticom (see here previously) is to accelerate the development of its oral IL-17 inhibitor program, targeting improved treatments for autoimmune diseases.

https://www.afhu.org/2025/01/09/revolutionizing-ai-driven-peptide-therapeutics-strengthening-pipeline-for-next-generation-drug-discovery-based-on-research-at-the-hebrew-university/